Nothing Special   »   [go: up one dir, main page]

Tian et al., 2019 - Google Patents

Development of a novel anti-tumor theranostic platform: a near-infrared molecular upconversion sensitizer for deep-seated cancer photodynamic therapy

Tian et al., 2019

View HTML
Document ID
4174761940208161013
Author
Tian R
Sun W
Li M
Long S
Li M
Fan J
Guo L
Peng X
Publication year
Publication venue
Chemical Science

External Links

Snippet

Upconversion-based photon-initiated therapeutic modalities, photodynamic therapy (PDT) in particular, have shown significant clinical potential in deep-seated tumor treatment. However, traditional multiphoton upconversion materials involving lanthanide (ion)-doped …
Continue reading at pubs.rsc.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Similar Documents

Publication Publication Date Title
Tian et al. Development of a novel anti-tumor theranostic platform: a near-infrared molecular upconversion sensitizer for deep-seated cancer photodynamic therapy
Zhu et al. Zwitterionic AIEgens: Rational Molecular Design for NIR‐II Fluorescence Imaging‐Guided Synergistic Phototherapy
Zou et al. Penetration depth tunable BODIPY derivatives for pH triggered enhanced photothermal/photodynamic synergistic therapy
Zou et al. A single molecule drug targeting photosensitizer for enhanced breast cancer photothermal therapy
Zhou et al. Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy
Yang et al. Bismuth ferrite‐based nanoplatform design: an ablation mechanism study of solid tumor and NIR‐triggered photothermal/photodynamic combination cancer therapy
Lan et al. Carbon dots as multifunctional phototheranostic agents for photoacoustic/fluorescence imaging and photothermal/photodynamic synergistic cancer therapy
Pan et al. Dual channel activatable cyanine dye for mitochondrial imaging and mitochondria-targeted cancer theranostics
Zhang et al. Ultra‐Small Nano‐Assemblies as Tumor‐Targeted and Renal Clearable Theranostic Agent for Photodynamic Therapy
Zeng et al. An ultrasound‐excitable aggregation‐induced emission dye for enhanced sonodynamic therapy of tumors
Cui et al. Stable π-radical nanoparticles as versatile photosensitizers for effective hypoxia-overcoming photodynamic therapy
Wang et al. A glutathione activatable photosensitizer for combined photodynamic and gas therapy under red light irradiation
Huang et al. Near infrared boron dipyrromethene nanoparticles for optotheranostics
Xiong et al. A singlet oxygen self-reporting photosensitizer for cancer phototherapy
Zhang et al. Perylenediimide chromophore as an efficient photothermal agent for cancer therapy
Jiang et al. A mitochondrion-targeting two-photon photosensitizer with aggregation-induced emission characteristics for hypoxia-tolerant photodynamic therapy
Yao et al. Single-atom engineering of hemicyanine and its amphiphilic derivative for optimized near infrared phototheranostics
Sun et al. pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors
Cao et al. Three birds with one stone: acceptor engineering of hemicyanine dye with NIR‐II emission for synergistic photodynamic and photothermal anticancer therapy
US20240041787A1 (en) Photosensitizer molecule and use thereof in increasing tumor retention time and enhancing treatment of large-volume tumors
He et al. D‐type neuropeptide decorated AIEgen/RENP hybrid nanoprobes with light‐driven ROS generation ability for NIR‐II fluorescence imaging‐guided through‐skull photodynamic therapy of gliomas
Zhou et al. A lysosomal targeted NIR photosensitizer for photodynamic therapy and two-photon fluorescence imaging
Chen et al. NIR photosensitizer for two-photon fluorescent imaging and photodynamic therapy of tumor
Li et al. Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer
Xia et al. Near-infrared organic fluorescent nanoparticles for long-term monitoring and photodynamic therapy of cancer